Immunogenicity Risk Assessment for Nucleic Acid Therapeutics
Date: September 24, 2026 Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies Description: Nucleic acid therapeutics require new immunogenicity evaluation frameworks, as the safety ...
Trainee Spotlight Series: 2025 Oligo Meeting Poster Winners 6
Date: September 17, 2026 Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Streamlining Exon-Skipping Antisense Oligonucleotide Therapy Development Via a High-Throughput Approach Description: Disease-modifying therapies are available for <5% of the >7000 described rare genetic diseases (RGDs). Antisense oligonucleotides (ASOs) represent ...
Advancing Precision Medicine: Oligonucleotide Therapeutics and Genome Editing
Date: June 18, 2026 Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Advancing Precision Medicine: Oligonucleotide Therapeutics and Genome Editing Description: The advent of programmable therapeutics — from oligonucleotide drugs to genome editing technologies — is transforming the treatment landscape for ...
Chance, Choice, and Conviction: A Career in Oligonucleotide Therapeutics
Date: June 4, 2026 Time: 11am-12pm EDT / 5-6pm CEST Register Here Title: Chance, Choice, and Conviction: A Career in Oligonucleotide Therapeutics Description: An insight into how a combination of (taking) chance, role models, mentors, becoming better at making informed decisions, and ...
Bioanalysis of Oligonucleotide Therapeutics via Nucleic Acid Nanorobotic Platform
Date: May 21, 2026 Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Bioanalysis of Oligonucleotide Therapeutics via Nucleic Acid Nanorobotic Platform Description: Dynamic DNA nanotechnology enables the isothermal and enzyme-free exchange of nucleic acid strands. The underlying mechanism of action in ...
